Pharmacogenomics: How Your Genes Affect Medications

Pharmacogenomics studies how genetic variants in enzymes like CYP2C19, CYP2D6, CYP2C9, VKORC1, and DPYD determine whether drugs work, fail, or cause adverse effects. CPIC guidelines provide evidence-based prescribing recommendations based on genetic phenotype.

Key Pharmacogenes

CYP2C19 affects clopidogrel (Plavix) activation and SSRI metabolism. VKORC1 and CYP2C9 determine warfarin sensitivity. DPYD variants cause severe toxicity with 5-fluorouracil chemotherapy. SLCO1B1 affects statin-induced myopathy risk. GenomeNarrator covers 26 CPIC Level A and B genes. See the full analysis at our genomic report page or learn about GWAS research methods.

Star Allele Nomenclature

Pharmacogenomic variants are described using star allele notation (e.g., CYP2C19*2, *17). Diplotype combinations predict metabolizer phenotype: poor, intermediate, normal, rapid, or ultrarapid. These phenotypes are cross-referenced against CPIC drug dosing guidelines and the PharmGKB database. Return to GenomeNarrator home or view pricing.